Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption.
暂无分享,去创建一个
[1] S. Kitagawa,et al. Inhibition of P‐glycoprotein function by tea catechins in KB‐C2 cells , 2004, The Journal of pharmacy and pharmacology.
[2] L. Benet,et al. Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. , 2004, International journal of pharmaceutics.
[3] J. Crison,et al. A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability , 1995, Pharmaceutical Research.
[4] R. Löbenberg,et al. Current perspectives in dissolution testing of conventional and novel dosage forms. , 2007, International journal of pharmaceutics.
[5] R. Kim,et al. Effect of Grapefruit Juice Volume on the Reduction of Fexofenadine Bioavailability: Possible Role of Organic Anion Transporting Polypeptides , 2005, Clinical pharmacology and therapeutics.
[6] Y. Sugiyama,et al. Apical/Basolateral Surface Expression of Drug Transporters and its Role in Vectorial Drug Transport , 2005, Pharmaceutical Research.
[7] Y. Sawada,et al. CITRUS JUICES INHIBIT THE FUNCTION OF HUMAN ORGANIC ANION-TRANSPORTING POLYPEPTIDE OATP-B , 2005, Drug Metabolism and Disposition.
[8] P. Welling. THE EFFECTS OF FOOD ON DRUG ABSORPTION , 1996, Annual review of nutrition.
[9] J. Tack,et al. Parallel Monitoring of Plasma and Intraluminal Drug Concentrations in Man After Oral Administration of Fosamprenavir in the Fasted and Fed State , 2007, Pharmaceutical Research.
[10] T. Abe,et al. Transcellular Transport of Organic Anions Across a Double-transfected Madin-Darby Canine Kidney II Cell Monolayer Expressing Both Human Organic Anion-transporting Polypeptide (OATP2/SLC21A6) and Multidrug Resistance-associated Protein 2 (MRP2/ABCC2)* , 2002, The Journal of Biological Chemistry.
[11] J. Leyden,et al. Absorption of minocycline hydrochloride and tetracycline hydrochloride. Effect of food, milk, and iron. , 1985, Journal of the American Academy of Dermatology.
[12] Leslie Z. Benet,et al. Predicting Drug Disposition via Application of BCS: Transport/Absorption/ Elimination Interplay and Development of a Biopharmaceutics Drug Disposition Classification System , 2004, Pharmaceutical Research.
[13] P. Tso,et al. Intestinal Lipid Absorption , 2009 .
[14] R. Kim. Transporters and drug discovery: why, when, and how. , 2006, Molecular pharmaceutics.
[15] B. Boyd,et al. Drug Solubilization Behavior During in Vitro Digestion of Suspension Formulations of Poorly Water-Soluble Drugs in Triglyceride Lipids , 2004, Pharmaceutical Research.
[16] P. Marathe,et al. Development and validation of a preclinical food effect model. , 2007, Journal of pharmaceutical sciences.
[17] Christel A. S. Bergström,et al. In silico predictions of drug solubility and permeability: two rate-limiting barriers to oral drug absorption. , 2005, Basic & clinical pharmacology & toxicology.
[18] H vandeWaterbeemd,et al. The fundamental variables of the biopharmaceutics classification system (BCS): a commentary. , 1998 .
[19] L. Benet,et al. Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. , 2002, The Journal of pharmacology and experimental therapeutics.
[20] P. Gershkovich,et al. Effect of a high-fat meal on absorption and disposition of lipophilic compounds: the importance of degree of association with triglyceride-rich lipoproteins. , 2007, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[21] S. Frokjaer,et al. Optimized conditions for MDCK permeability and turbidimetric solubility studies using compounds representative of BCS classes I-IV. , 2002, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[22] Gordon L Amidon,et al. A Mechanistic Approach to Understanding the Factors Affecting Drug Absorption: A Review of Fundamentals , 2002, Journal of clinical pharmacology.
[23] J. Polli,et al. Rational use of in vitro P-glycoprotein assays in drug discovery. , 2001, The Journal of pharmacology and experimental therapeutics.
[24] H. Lennernäs,et al. The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique. , 2003, British journal of clinical pharmacology.
[25] U. Fagerholm. Prediction of human pharmacokinetics —gastrointestinal absorption , 2007, The Journal of pharmacy and pharmacology.
[26] G. Jang,et al. Dietary Effects on Drug Metabolism and Transport , 2003, Clinical pharmacokinetics.
[27] Kazuya Maeda,et al. Identification of the Hepatic Efflux Transporters of Organic Anions Using Double-Transfected Madin-Darby Canine Kidney II Cells Expressing Human Organic Anion-Transporting Polypeptide 1B1 (OATP1B1)/Multidrug Resistance-Associated Protein 2, OATP1B1/Multidrug Resistance 1, and OATP1B1/Breast Cancer R , 2005, Journal of Pharmacology and Experimental Therapeutics.
[28] Jennifer B Dressman,et al. Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system. , 2004, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[29] Dennis A. Smith. Design of drugs through a consideration of drug metabolism and pharmacokinetics , 1994, European Journal of Drug Metabolism and Pharmacokinetics.
[30] D. Fleisher,et al. Meal Composition Effects on the Oral Bioavailability of Indinavir in HIV-Infected Patients , 1999, Pharmaceutical Research.
[31] R. Béliveau,et al. Inhibition of P-glycoprotein transport function and reversion of MDR1 multidrug resistance by cnidiadin , 2005, Cancer Chemotherapy and Pharmacology.
[32] Brahma N. Singh. A quantitative approach to probe the dependence and correlation of food‐effect with aqueous solubility, dose/solubility ratio, and partition coefficient (Log P) for orally active drugs administered as immediate‐release formulations , 2005 .
[33] L. Benet,et al. Effect of Food on the Pharmacokinetics of Cyclosporine in Healthy Subjects Following Oral and Intravenous Administration , 1990, Journal of clinical pharmacology.
[34] Y. Kashiwada,et al. Effects of alkyl gallates on P-glycoprotein function. , 2005, Biochemical pharmacology.
[35] W. Charman,et al. Lipid-based vehicles for the oral delivery of poorly water soluble drugs , 1997 .
[36] G. Edwards,et al. Association of halofantrine with postprandially derived plasma lipoproteins decreases its clearance relative to administration in the fasted state. , 1998, Journal of pharmaceutical sciences.
[37] Shuzhong Zhang,et al. Effects of the Flavonoids Biochanin A, Morin, Phloretin, and Silymarin on P-Glycoprotein-Mediated Transport , 2003, Journal of Pharmacology and Experimental Therapeutics.
[38] Y. Masaoka,et al. Effect of food intake on the oral absorption of poorly water-soluble drugs: in vitro assessment of drug dissolution and permeation assay system. , 2006, Journal of pharmaceutical sciences.
[39] Shiyin Yee,et al. In Vitro Permeability Across Caco-2 Cells (Colonic) Can Predict In Vivo (Small Intestinal) Absorption in Man—Fact or Myth , 1997, Pharmaceutical Research.
[40] B. H. Stewart,et al. Transport properties are not altered across Caco-2 cells with heightened TEER despite underlying physiological and ultrastructural changes. , 1996, Journal of pharmaceutical sciences.
[41] S. Chong,et al. Effect of fruit juices on the oral bioavailability of fexofenadine in rats. , 2005, Journal of pharmaceutical sciences.
[42] B. Boyd,et al. Influence of the intermediate digestion phases of common formulation lipids on the absorption of a poorly water-soluble drug. , 2005, Journal of pharmaceutical sciences.
[43] H Lennernäs,et al. Human Jejunal Effective Permeability and Its Correlation with Preclinical Drug Absorption Models , 1997, The Journal of pharmacy and pharmacology.
[44] R. B. Parker,et al. Effects of Grapefruit Juice on Intestinal P‐glycoprotein: Evaluation Using Digoxin in Humans , 2003, Pharmacotherapy.
[45] L. Benet,et al. Glucuronidation and the transport of the glucuronide metabolites in LLC-PK1 cells. , 2005, Molecular Pharmaceutics.
[46] W. L. Jorgensen,et al. Prediction of drug solubility from structure. , 2002, Advanced drug delivery reviews.
[47] G. Amidon,et al. Comparison of gastrointestinal pH in dogs and humans: implications on the use of the beagle dog as a model for oral absorption in humans. , 1986, Journal of pharmaceutical sciences.
[48] J. Dressman,et al. In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[49] Gordon L. Amidon,et al. Comparison of Human Duodenum and Caco-2 Gene Expression Profiles for 12,000 Gene Sequences Tags and Correlation with Permeability of 26 Drugs , 2002, Pharmaceutical Research.
[50] Kazuhiro Watanabe,et al. Studies on intestinal absorption of sulpiride (2): transepithelial transport of sulpiride across the human intestinal cell line Caco-2. , 2002, Biological & pharmaceutical bulletin.
[51] Ben J Boyd,et al. Probing drug solubilization patterns in the gastrointestinal tract after administration of lipid-based delivery systems: a phase diagram approach. , 2004, Journal of pharmaceutical sciences.
[52] Vinod P. Shah,et al. Biopharmaceutics Classification System: The Scientific Basis for Biowaiver Extensions , 2002, Pharmaceutical Research.
[53] S. Hladky,et al. Modulatory effects of plant phenols on human multidrug‐resistance proteins 1, 4 and 5 (ABCC1, 4 and 5) , 2005, The FEBS journal.
[54] Alex Avdeef,et al. Physicochemical Profiling (Solubility, Permeability and Charge State) , 2001 .
[55] P. Augustijns,et al. Biological, pharmaceutical, and analytical considerations with respect to the transport media used in the absorption screening system, Caco-2. , 2003, Journal of pharmaceutical sciences.
[56] E. D. Barnhart. Physicians Desk Reference , 1990 .
[57] D. Shen,et al. First‐pass metabolism of midazolam by the human intestine , 1996, Clinical pharmacology and therapeutics.
[58] Yuichi Sugiyama,et al. Inhibition of Bile Acid Transport across Na+/Taurocholate Cotransporting Polypeptide (SLC10A1) and Bile Salt Export Pump (ABCB 11)-Coexpressing LLC-PK1 Cells by Cholestasis-Inducing Drugs , 2006, Drug Metabolism and Disposition.
[59] Wilhelm Kirch,et al. Grapefruit Juice Ingestion Significantly Reduces Talinolol Bioavailability , 2005, Clinical pharmacology and therapeutics.
[60] J. Spence,et al. Ethanol enhances the hemodynamic effects of felodipine. , 1989, Clinical and investigative medicine. Medecine clinique et experimentale.
[61] J. DeSesso,et al. Anatomical and physiological parameters affecting gastrointestinal absorption in humans and rats. , 2001, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[62] Lawrence X. Yu,et al. Effect of common excipients on Caco-2 transport of low-permeability drugs. , 2001, Journal of pharmaceutical sciences.
[63] K. Raghavan,et al. Predicting Effect of Food on Extent of Drug Absorption Based on Physicochemical Properties , 2007, Pharmaceutical Research.
[64] D. Brocks,et al. The influence of lipids on stereoselective pharmacokinetics of halofantrine: Important implications in food-effect studies involving drugs that bind to lipoproteins. , 2002, Journal of pharmaceutical sciences.
[65] P. Dawson,et al. Fruit juices inhibit organic anion transporting polypeptide–mediated drug uptake to decrease the oral availability of fexofenadine , 2002, Clinical pharmacology and therapeutics.
[66] K. Wasan,et al. Effect of Lipid Excipients on In Vitro Pancreatic Lipase Activity , 2003, Drug development and industrial pharmacy.
[67] Kazuhiro Watanabe,et al. Studies on intestinal absorption of sulpiride (1): carrier-mediated uptake of sulpiride in the human intestinal cell line Caco-2. , 2002, Biological & pharmaceutical bulletin.
[68] J. Dressman,et al. Media to simulate the postprandial stomach I. Matching the physicochemical characteristics of standard breakfasts , 2004, The Journal of pharmacy and pharmacology.
[69] R. Löbenberg,et al. Evaluation of Various Dissolution Media for Predicting In Vivo Performance of Class I and II Drugs , 1998, Pharmaceutical Research.
[70] Per Artursson,et al. Expression of Thirty-six Drug Transporter Genes in Human Intestine, Liver, Kidney, and Organotypic Cell Lines , 2007, Drug Metabolism and Disposition.
[71] Michael Boyd,et al. Potential Mechanisms by Which Peceol® Increases the Gastrointestinal Absorption of Amphotericin B , 2004, Drug development and industrial pharmacy.
[72] Joachim Grevel,et al. Influence of a Fat-Rich Meal on the Pharmacokinetics of a New Oral Formulation of Cyclosporine in a Crossover Comparison with the Market Formulation , 2004, Pharmaceutical Research.
[73] J. Kovarik,et al. Minor influence of a fat-rich meal on the pharmacokinetics of a new oral formulation of cyclosporine. , 1994, Transplantation proceedings.
[74] J. Dressman,et al. Physiochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH. , 1997, Journal of pharmaceutical sciences.
[75] M. Morris,et al. Effect of Organic Isothiocyanates on the P-Glycoprotein- and MRP1-Mediated Transport of Daunomycin and Vinblastine , 2002, Pharmaceutical Research.
[76] C. Lipinski. Drug-like properties and the causes of poor solubility and poor permeability. , 2000, Journal of pharmacological and toxicological methods.
[77] J. Polli,et al. Apical sodium dependent bile acid transporter (ASBT, SLC10A2): a potential prodrug target. , 2006, Molecular pharmaceutics.
[78] D. Fleisher,et al. Drug, Meal and Formulation Interactions Influencing Drug Absorption After Oral Administration , 1999, Clinical pharmacokinetics.
[79] S. Ambudkar,et al. Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells. , 2002, Biochemical pharmacology.
[80] Brahma N. Singh. Effects of Food on Clinical Pharmacokinetics , 1999, Clinical pharmacokinetics.
[81] Christel A. S. Bergström,et al. Computational models to predict aqueous drug solubility, permeability and intestinal absorption , 2005, Expert opinion on drug metabolism & toxicology.
[82] M. Ratain,et al. The value meal: how to save $1,700 per month or more on lapatinib. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[83] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .
[84] H. Liedholm,et al. Concomitant food intake can increase the bioavailability of propranolol by transient inhibition of its presystemic primary conjugation , 1986, Clinical pharmacology and therapeutics.
[85] J. Polli,et al. Development of Stably Transfected Monolayer Overexpressing the Human Apical Sodium-Dependent Bile Acid Transporter (hASBT) , 2005, Pharmaceutical Research.
[86] D. Keppler,et al. Vectorial Transport of the Peptide CCK-8 by Double-Transfected MDCKII Cells Stably Expressing the Organic Anion Transporter OATP1B3 (OATP8) and the Export Pump ABCC2 , 2005, Journal of Pharmacology and Experimental Therapeutics.
[87] István Antal,et al. In vitro simulation of food effect on dissolution of deramciclane film-coated tablets and correlation with in vivo data in healthy volunteers. , 2002, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[88] I. Kanfer. Report on the International Workshop on the Biopharmaceutics Classification System (BCS): scientific and regulatory aspects in practice. , 2002, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.
[89] H. Lennernäs,et al. A Clinical Single-Pass Perfusion Investigation of the Dynamic in Vivo Secretory Response to a Dietary Meal in Human Proximal Small Intestine , 2006, Pharmaceutical Research.
[90] Raimar Löbenberg,et al. Biorelevant dissolution media as a predictive tool for glyburide a class II drug. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[91] P Augustijns,et al. Simulated intestinal fluid as transport medium in the Caco-2 cell culture model. , 2002, International journal of pharmaceutics.
[92] K. Aizawa,et al. A bitter melon extract inhibits the P‐glycoprotein activity in intestinal Caco‐2 cells: Monoglyceride as an active compound , 2004, BioFactors.
[93] H. Lennernäs,et al. Transport Characteristics of Fexofenadine in the Caco-2 Cell Model , 2004, Pharmaceutical Research.
[94] J. Dressman,et al. Characterization of the Human Upper Gastrointestinal Contents Under Conditions Simulating Bioavailability/Bioequivalence Studies , 2006, Pharmaceutical Research.
[95] D. Small,et al. Lipid digestion and absorption. , 1983, Annual review of physiology.
[96] B. Schug,et al. The biopharmaceutics classification system (BCS): class III drugs - better candidates for BA/BE waiver? , 1999, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[97] G. M. Pollack,et al. Intestinal Absorptive Transport of the Hydrophilic Cation Ranitidine: A Kinetic Modeling Approach to Elucidate the Role of Uptake and Efflux Transporters and Paracellular vs. Transcellular Transport in Caco-2 Cells , 2006, Pharmaceutical Research.
[98] P. Langguth,et al. Compound mixtures in Caco-2 cell permeability screens as a means to increase screening capacity. , 2001, Die Pharmazie.
[99] D. Jung,et al. Effect of Food on the Relative Bioavailability of Oral Ganciclovir , 1996, Journal of clinical pharmacology.
[100] J. Polli,et al. Midazolam Exhibits Characteristics of a Highly Permeable P-Glycoprotein Substrate , 2003, Pharmaceutical Research.
[101] G. Amidon,et al. The effect of amiloride on the in vivo effective permeability of amoxicillin in human jejunum: experience from a regional perfusion technique. , 2002, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[102] R. Löbenberg,et al. Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. , 2000, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[103] U. Christians,et al. CYP3A4-Transfected Caco-2 Cells as a Tool for Understanding Biochemical Absorption Barriers: Studies with Sirolimus and Midazolam , 2004, Journal of Pharmacology and Experimental Therapeutics.
[104] Leslie Z Benet,et al. In Vivo Modulation of Intestinal CYP3A Metabolism by P-Glycoprotein: Studies Using the Rat Single-Pass Intestinal Perfusion Model , 2003, Journal of Pharmacology and Experimental Therapeutics.
[105] D. Roden,et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. , 1998, The Journal of clinical investigation.
[106] K. Aizawa,et al. Inhibitory effect of a bitter melon extract on the P‐glycoprotein activity in intestinal Caco‐2 cells , 2004, British journal of pharmacology.
[107] A. Ungell,et al. Variability in mRNA expression of ABC- and SLC-transporters in human intestinal cells: comparison between human segments and Caco-2 cells. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[108] L. Johnson,et al. Physiology of the gastrointestinal tract , 2012 .
[109] Thierry Lavé,et al. Predicting Pharmacokinetic Food Effects Using Biorelevant Solubility Media and Physiologically Based Modelling , 2006, Clinical pharmacokinetics.
[110] Yuichi Sugiyama,et al. Transporters as a determinant of drug clearance and tissue distribution. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[111] P. Artursson,et al. Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[112] C. Porter,et al. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs , 2007, Nature Reviews Drug Discovery.
[113] Michael Levin. Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System , 2001 .
[114] Christel A. S. Bergström,et al. Absorption classification of oral drugs based on molecular surface properties. , 2003, Journal of medicinal chemistry.
[115] Patrick J. Sinko,et al. Estimating Human Oral Fraction Dose Absorbed: A Correlation Using Rat Intestinal Membrane Permeability for Passive and Carrier-Mediated Compounds , 2004, Pharmaceutical Research.
[116] B. Vig,et al. Peptide transporter substrate identification during permeability screening in drug discovery: Comparison of transfected MDCK-hPepT1 cells to caco-2 cells , 2007, Archives of pharmacal research.
[117] G. Dresser,et al. The effects of fruit juices on drug disposition: a new model for drug interactions , 2003, European journal of clinical investigation.
[118] L. Benet,et al. Effect of OATP1B Transporter Inhibition on the Pharmacokinetics of Atorvastatin in Healthy Volunteers , 2007, Clinical pharmacology and therapeutics.
[119] P. Sinko,et al. Intestinal drug transporters: in vivo function and clinical importance. , 2004, Current drug metabolism.
[120] L. Benet,et al. Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data. , 2003, Current drug metabolism.
[121] P. Gershkovich,et al. The effect of a high-fat meal on the pharmacodynamics of a model lipophilic compound that binds extensively to triglyceride-rich lipoproteins. , 2007, International journal of pharmaceutics.
[122] Y. Sawada,et al. EFFECTS OF HERBAL EXTRACTS ON THE FUNCTION OF HUMAN ORGANIC ANION-TRANSPORTING POLYPEPTIDE OATP-B , 2006, Drug Metabolism and Disposition.